Algorithm for the management of patients with prediabetes or T2DM and definite NASH. This suggested therapeutic algorithm is based on the safety and efficacy.

Slides:

Advertisements

Similar presentations

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

Advertisements

Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:

TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.

JBS2 Some highlights from the JBS2 guidelines on prevention of cardiovascular disease in clinical practice Jim McMorran GP trainer Visiting Senior Clinical.

AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.

ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.

Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A.

Canagliflozin Cardiovascular Safety. 2 Potential CV protection pathways of SGLT2i Diab Vasc Dis Res Mar;12(2):

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Safety and Efficacy of Low Blood Pressures Among.

Improving risk factor management for patients with poorly controlled type 2 diabetes: a systematic review of non-pharmaceutical interventions in primary.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.

Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: The CardioMetabolic Health Alliance: Working Toward.

Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Insulin Therapy for Type 2 Diabetes Mellitus JAMA.

Case-Based Examination of Treatment Options in Type 2 Diabetes Management.

Copyright © 2015 by the American Osteopathic Association.

Vanguard Phase Results for the Blood Pressure Component

Copyright © 2002 American Medical Association. All rights reserved.

Copyright © 2008 American Medical Association. All rights reserved.

(B.P :51) ( B:P52 ).

Circ Cardiovasc Qual Outcomes

51st Annual Scientific Session for the LIFE Investigators

Systolic Blood Pressure Intervention Trial (SPRINT)

Prediabetes Screening and Monitoring

Strategies to Improve Adherence and Persistence in the Treatment of Hypertension.

Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

Pharmacist-to-prescriber intervention to close therapeutic gaps for statin use in patients with diabetes: A randomized controlled trial Hannah M. Renner,

Figure 5 Risk factor control in the intensive treatment group

Antihyperglycemic therapy in type 2 diabetes: general recommendations

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.

Prevalence of NAFLD (panel A) and advanced fibrosis (panel B) in the general population and in patients with T2DM according to different diagnostic tools.

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

Cardiovascular disease in women with HIV-1 infection

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

Side-by-side comparison of change in A1C with canagliflozin versus DPP-4 inhibitors in randomized clinical trials and the real-world study. *Data are LS.

Volume 62, Issue 4, Pages (October 2002)

Flow of Patients Through Trial

Comparison of clinical and functional parameters between the CMV+ and CMV− participants in the healthy elderly and elderly patients with T2DM. Comparison.

Algorithm for the diagnosis of NAFLD and NASH in patients with prediabetes or T2DM in clinical practice. Algorithm for the diagnosis of NAFLD and NASH.

(A) Rate of achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in all subjects and (B) prevalence of nephropathy, retinopathy,

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Carmine Zoccali, Francesca Mallamaci Kidney International

Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world.

Completed and ongoing CVOTs (6–14,39,44–58)

Demonstration of the cascade of clinical events and metabolic changes that contribute sequentially to progressive clinical deterioration and development.

Incidence rates and HRs for total cardiovascular events and stroke stratified by the TCF7L2-rs polymorphism and the dietary intervention group after.

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.

An algorithm depicting the basic approach to the Charcot foot

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Algorithm for the metabolic management of type 2 diabetes; Reinforce lifestyle interventions at every visit and check A1C every 3 months until A1C is

FMD and PWV of patients with diabetes with (T2DM-SCT) or without (T2DM) SCT and of healthy individuals with (SCT) or without (CONT) SCT. FMD measured at.

Forefoot peak plantar pressure in diabetic patients without and with mild, moderate, and severe peripheral neuropathy. *Severe and moderate neuropathy.

Diabetes intervention (ACM) and control (TTR-only) care package details. ACM = additional case management. BP = blood pressure. FBG = fasting blood glucose.

Two-year changes in albumin-to-creatinine ratio across microalbuminuria at baseline. Two-year changes in albumin-to-creatinine ratio across microalbuminuria.

What's New in Oral Combination Therapy for Type 2 Diabetes?

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.

Mean adjusted levels in each group for the following cardiometabolic risk factors at 3 and 12 months postpartum: (A) systolic blood pressure, (B) diastolic.

Several genetic, environmental, lipid partitioning, and biochemical factors, shown on the left, promote the development of subclinical inflammation and.

Number of antihypertensive agents prescribed for known nephropaths in phases I and II (▪), with blood pressure recordings falling outside guidelines, compared.

Percent binding of cross-reactive antibodies from cross-over studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

The figure shows lack of strong evidence for vitamin D therapy to prevent cardiovascular disease in CKD. Although epidemiologic studies suggest a relationship.

Percent binding of cross-reactive antibodies from parallel studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

Pathway to initial antihypertensive therapy in patients with diabetes

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.

Mean BP by visit - all patients

Upper panel: For performance of the 10-g monofilament test, the device is placed perpendicular to the skin, with pressure applied until the monofilament.

Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients

Hepatic triglyceride content (A), hepatic insulin resistance index (B), and hepatic VLDL1-triglyceride production (C) in responders and nonresponders at.

Adjusted HRs for death from any cause and death from specific causes among patients with type 1 diabetes. Adjusted HRs for death from any cause and death.

Presentation transcript:

Algorithm for the management of patients with prediabetes or T2DM and definite NASH. This suggested therapeutic algorithm is based on the safety and efficacy of interventions assessed in randomized controlled trials. Algorithm for the management of patients with prediabetes or T2DM and definite NASH. This suggested therapeutic algorithm is based on the safety and efficacy of interventions assessed in randomized controlled trials. BP, blood pressure; CV, cardiovascular; TG, triglyceride. Fernando Bril, and Kenneth Cusi Dia Care 2017;40:419-430 ©2017 by American Diabetes Association